Skip to main navigation Skip to search Skip to main content

Preventive intrapulmonary treatment with Ligilactobacillus murinus reduces airway inflammation and mucus plugging in mice with cystic fibrosis-like lung disease.

  • Robert Brock
  • , Laura Schaupp
  • , André Schütte
  • , Zhe Zhou-Suckow
  • , Simone Butz
  • , Jolanthe Schatterny
  • , Selina Mayer
  • , Angela Frank
  • , Jan Philipp Mengel
  • , Markus Weigel
  • , Torsten Hain
  • , Alexander Dalpke
  • , Sébastien Boutin
  • , Marcus A Mall
  • Ruprecht-Karls Universität Heidelberg
  • Hannover Medical School
  • Hessian State Office for Health and Care
  • University of Giessen

Abstract

BACKGROUND: Chronic airway dysbiosis plays an important role in the pathogenesis of cystic fibrosis (CF) lung disease and may serve as a therapeutic target. However, studies investigating the effects of direct therapeutic targeting of the airway microbiome are lacking. In this study, we therefore used βENaC-overexpressing (βENaC-Tg) mice and determined the evolution of abnormal lung microbiota and effects of re-balancing bacterial communities on chronic airway inflammation and mucus plugging in this model of CF lung disease.

METHODS: The development of the respiratory microbiome was determined by 16S rRNA gene sequencing and the effects of preventive intranasal instillation of endogenous probiotic bacteria on the lung phenotype were determined in βENaC-Tg mice and wild-type littermates.

RESULTS: Neonatal βENaC-Tg mice developed severe respiratory dysbiosis characterised by an increase in the relative abundance of Streptococcus and a decrease in Ligilactobacillus compared to wild-type littermates. Ligilactobacillus murinus SMH17 was identified as the dominant Ligilactobacillus species in the lungs of neonatal wild-type mice. Preventive treatment by intranasal instillation of L. murinus SMH17 was well tolerated and reduced age-specific markers of airway inflammation including inflammatory cell counts and proinflammatory cytokines in neonatal and juvenile βENaC-Tg mice. In addition, preventive treatment with L. murinus SMH17 reduced airway mucus plugging in βENaC-Tg mice by ∼40%.

CONCLUSION: Preventive intrapulmonary application of the endogenous probiotic L. murinus SMH17 reduces airway inflammation and mucus plugging in mice with CF-like lung disease. These data support further elucidation of inhaled probiotics as a strategy to treat chronic airway dysbiosis in patients with CF.

Original languageEnglish
Article number00086-2026
JournalERJ Open Research
Volume12
Issue number4
Pages (from-to)00086-2026
Number of pages1,941
ISSN2312-0541
Publication statusPublished - 07.2026

Funding

FundersFunder number
Bundesministerium für Forschung, Technologie und Raumfahrt82DZL009C1, 82DZL004A1, 82DZL00401, 01GL2401A
Deutsche ForschungsgemeinschaftEXC 3118/1 – project number 533770413, SFB1021 Z02, SFB 1449 – project ID 431232613 Z02, SFB-TR84 B08, B05, SFB 1449 – project ID 431232613 B05, Z02, SFB 1449 – project ID 431232613 A01, KFO309 Z1
European Commission Framework 7 programme CFMATTERS603038

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being
    2. SDG 6 - Clean Water and Sanitation
      SDG 6 Clean Water and Sanitation

    Fingerprint

    Dive into the research topics of 'Preventive intrapulmonary treatment with Ligilactobacillus murinus reduces airway inflammation and mucus plugging in mice with cystic fibrosis-like lung disease.'. Together they form a unique fingerprint.

    Cite this